Alnylam Pharmaceuticals (ALNY), the RNA therapeutics developer, rose 4% after announcing a strategic AI partnership with Inceptive Nucleics worth up to $2bn. The collaboration will use generative AI to accelerate the discovery of RNA interference therapies.